Product Description
Ciclesonide is used to help prevent the symptoms of asthma. When used regularly every day, inhaled ciclesonide decreases the number and severity of asthma attacks. However, it will not relieve an asthma attack that has already started. Ciclesonide is a corticosteroid or steroid (cortisone-like medicine). It works by preventing inflammation (swelling) in the lungs, which makes the asthma attack less severe . (Sourced from: https://www.mayoclinic.org/drugs-supplements/ciclesonide-inhalation-route/side-effects/drg-20071477?p=1)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Inhalant,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Seasonal | Spasm | Asthma
Known Adverse Events: Headache | Epistaxis | Back Pain | Pain Unspecified | Nasopharyngitis | Pharyngitis | Arthralgia | Sinusitis
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROTECT-V | P3 |
Recruiting |
COVID-19 |
2024-07-01 |